Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

Cancer Research

Volumn 67, Issue 22, 2007, Pages 11021-11028

  Nefedova, Yulia ^a   Fishman, Mayer ^a   Sherman, Simon ^b   Wang, Xingyu ^a   Beg, Amer A ^a   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE; GLUTATHIONE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; RETINOIC ACID;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SUPPRESSOR CELL;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); REACTIVE OXYGEN SPECIES; TRETINOIN;

EID: 36348989162     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2593     Document Type: Article

References (37)

1. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-45.
2. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
3. Gabrilovich D, Bronte V, Chen S-H, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425.
4. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
5. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989-99.
6. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003;74:186-96.
7. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
8. + myeloid cells. J Immunol 2001;166:5398-406.
9. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441-9.
10. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006;66:9299-307.
11. Gervais A, Leveque J, Bouet-Toussaint F, et al. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res 2005;7:R326-35.
12. Mohty M, Morbelli S, Isnardon D, et al. All-trans retinoic acid skews monocyte differentiation into interleukin-12-secreting dendritic-like cells. Br J Haematol 2003;122:829-36.
13. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004;328:1-16.
14. Altucci A, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
15. Nefedova Y, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004;172:464-74.
16. + T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-92.
17. Gelderman K, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proc Natl Acad Sci U S A 2006;103:12831-6.
18. Maurice M, Nakamura H, van der Voort E, et al. Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis. J Immunol 1997;158:1458-65.
19. + T cells reveals an essential requirement for nuclear factor κB in regulating mature T cell survival and in vivo function. J Exp Med 2003;197:861-74.
20. + T cells. J Clin Invest 2006;116:2777-90.
21. Lee TD, Yang H, Whang J, Lu SC. Cloning and characterization of the human glutathione synthetase 5′-flanking region. Biochem J 2005;390:521-8.
22. Yang H, Magilnick N, Ou X, Lu SC. Tumour necrosis factor a induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor κB and activator protein-1. Biochem J 2005;391:399-408.
23. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65:9525-35.
24. Teixeira CC, Shapiro IM, Hatori M, Rajpurohit R, Koch C. Retinoic acid modulation of glutathione and cysteine metabolism in chondrocytes. Biochem J 1996;314:21-6.
25. Manzano VM, Puyol MR, Puyol DR, Cazana FJ. Tretinoin prevents age-related renal changes and stimulates antioxidant defenses in cultured renal mesangial cells. J Pharmacol Exp Ther 1999;289:123-32.
26. Mantymaa P, Guttorm T, Siitonen T, et al. Cellular redox state and its relationship to the inhibition of clonal cell growth and the induction of apoptosis during all-trans retinoic acid exposure in acute myeloblastic leukemia cells. Haematologica 2000;85:238-45.
27. Morales MC, Perez-Yarza G, Nieto-Rementeria N, et al. Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the antineoplasic agent N-(4-hydroxyphenyl) retinamide. Anticancer Res 2005;25:1945-51.
28. Brys L, Beschin A, Raes G, et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 2005;174:6095-104.
29. Sinha P, Clements V, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005;174:636-45.
30. Yanaka A, Zhang S, Tauchi M, et al. Role of the nrf-2 gene in protection and repair of gastric mucosa against oxidative stress. Inflammopharmacology 2005;13:83-90.
31. Moinova HR, Mulcahy RT. Up-regulation of the human γ- glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem Biophys Res Commun 1999;261:661-8.
32. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998;58:3163-72.
33. Yen A, Roberson MS, Varvayanis S. Retinoic acid selectively activates the ERK2 but not JNK/SAPK or p38 MAP kinases when inducing myeloid differentiation. In Vitro Cell Dev Biol Anim 1999;35:527-32.
34. Bost F, Caron L, Marchetti I, Dani C, Le Marchand-Brustel Y, Binetruy B. Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. Biochem J 2002;361:621-7.
35. Canon E, Cosgaya JM, Scsucova S, Aranda A. Rapid effects of retinoic acid on CREB and ERK phosphorylation in neuronal cells. Mol Biol Cell 2004;15:5583-92.
36. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667-79.
37. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-44.